Use of substituted gamma-lactone compounds as pharmaceutical preparations

Use of at least one substituted γ-lactone compound of the general formula I,

• 4
• in which
• R1 denotes an optionally at least mono-substituted 2-pyridyl, 2-pyrimidyl, 2-pyrazolyl, 2-quinolinyl or 2-pyrazinyl residue, which may also be fused with a saturated or at least partially unsaturated hydrocarbon ring system,
• R2 denotes an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C2-10 residue,
• R3 denotes an optionally at least mono-substituted aryl residue,
• R4 denotes H, or
• R3 and R4 together denote an optionally at least mono-substituted, saturated or at least mono-unsaturated aliphatic C3-7 residue, with the proviso that the residue R2 in this case denotes an optionally at least mono-substituted aryl residue, an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C2-10 residue,
• in the form of the racemates, diastereomers or enantiomers thereof as a free base or of a corresponding physiologically acceptable salt for the production of a pharmaceutical preparation for the treatment of migraine.